



Quidel to Present at the William Blair & Company Emerging Growth Stock Conference

September 22, 2009

SAN DIEGO--(BUSINESS WIRE)--Sep. 22, 2009-- **Quidel Corporation (NASDAQ:QDEL)**, a leading provider of rapid point-of-care diagnostic tests, today announced that it will present at the William Blair & Company 3rd Annual Emerging Growth Stock Conference to be held at the Waldorf-Astoria Hotel in New York City on Tuesday, October 6, 2009.

Douglas Bryant, president and chief executive officer, and John Radak, chief financial officer, will present that day at 1:15 p.m. Eastern time (10:15 p.m. Pacific time).

A live webcast and audio archive of the presentation will be available via the Investor Relations section of the company's Web site at www.quidel.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the company's Web site for 14 days.

About Quidel

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point-of-care in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue[®], Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment have an impact on clinical outcomes and provide an economic benefit. For more information, visit www.quidel.com, www.colorectal-test.com, www.rsvtesting.com and www.flutest.com.

Source: Quidel Corporation

Quidel Corporation
John M. Radak, Chief Financial Officer
(858) 646-8032
or
Porter Novelli Life Sciences
Pam Lord, (619) 849-6003
plord@pnlifesciences.com